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(54) Rearrangement of spirolactams
(57) The present invention refers to a process for rearranging a spirolactam (I) under acidic conditions to yield an
oxabicyclo [4.3.0] none (II) or (III) or a 1- aza- 2oxaspiro derivative (IV). The present invention also refers said oxabicyclo
[4.3.0]none and 1- aza- 2oxaspiro derivatives. 
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Description
FIELD OF THE INVENTION
[0001] The present invention refers to a process for rearranging a spirolactam to yield an oxabicyclo [4.3.0] none or a
1-aza- 2-oxaspiro derivative. The present invention also refers said oxabicyclo[4.3.0] none and 1- aza- 2-oxaspiro deriv-
atives.
BACKGROUND OF THE INVENTION
[0002] Tetrodotoxin (TTX), Octahydro-12-(hydroxymethyl)- 2- imino- 5,9: 7,10a- dimethano-10aH-[1,3] dioxocino[6,5-d]
pyrimidine-4,7,10,11,12-pentol, is a potent neurotoxin which selectively binds to sodium channel proteins inhibiting its
function in the cell membrane. Tetrodotoxin was first isolated in 1909 from the ovaries of the puffer fish, and named after
the puffer fish family "Tetraodontidae". Despite being a small molecule, it has an extremely complex structure charac-
terised by a dioxaadamantane skeleton, a guanidine residue at C2 which is part of a hemiaminal at C4, and an orthoacid
bridge at C10. As a result, TTX has 4 quaternary carbon atoms and 8 sterogenic centers.
[0003] It should also be noted that TTX is usually present as a mixture of two possible tautomers: an ortoester and a
hydroxyl lactone. The ratio of both tautomers depends on the media in which TTX is present.
[0004] Tetrodotoxin blocks diffusion of sodium through the voltage dependent sodium channel, preventing depolari-
zation and propagation of action potentials in nerve cells. The TTX-Na Channel binding site is extremely tight (Kd = 10-10
nM). Therefore it is an essential tool in pharmacological studies related to sodium channel proteins.
[0005] Further, Tetrodotoxin, due to its analgesic properties, is a promising new drug candidate in the field of pain
management. It is currently in phase III clinical trials for cancer pain.
[0006] Extraction and purification of natural TTX is complicated, and dependent on the availability of the right animal
source. Therefore there is an existing need of providing larger amounts of Tetrodotoxin and its analogues, and researchers
seek new cost effective and efficient synthesis. Up to the date, only a few total synthesis have been reported.
[0007] The first total synthesis of Tetrodotoxin was reported by Kishi in 1972 and afforded Tetrodotoxin as a racemic
mixture after 29 steps in a 0.66% overall yield (Kishi, Y.; Nakatsubo, F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi, H.;
Tetrahedron Lett. 1970, 59, 5127-5128; Kishi, Y.; Nakatsubo, F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi, H.; Tanino, H.;
Sugiura, S. J. Am. Chem. Soc. 1972, 94, 9217-9219; Kishi, Y.; Nakatsubo, F.; Aratani, M.; Goto, T.; Inoue, S.; Kakoi,
H.; Tanino, H.; Sugiura, S. J. Am. Chem. Soc. 1972, 94, 9219-9220; Kishi, Y.; Nakatsubo, F.; Aratani, M.; Goto, T.;
Inoue, S.; Kakoi, H.; Tanino, H.; Sugiura, S. J. Am. Chem. Soc. 1972, 94, 9220-9221).
[0008] The first asymmetric synthesis of Tetrodotoxin was reported by Isobe et al. in January 2003 (Isobe,M. et al,
J.Am.Chem.Soc, 2003, 125, 8798-8805). This synthesis relied in a Claissen rearrangement, a Shonogashira coupling
and an intramolecular carbamate-ester conjugate addition as key steps. After 67 steps Tetrodotoxin was obtained in a
1,22% overall yield.
[0009] Shortly after (June, 2003) Dubois et al. reported a second asymmetric synthesis of Tetrodotoxin having a
Rhodium-catalazed carbene and nitrene insertion as key step with an overall yield of 0.49% after 32 steps (Du Bois, J.;
Hinman, A. J. Am. Chem. Soc. 2003, 125, 11510-11511).
[0010] Recently, Isobe et al. have reported an additional asymmetric total synthesis comprising 62 steps and an overall
yield of approximately 1% from a vinilic methyl intermediate (Isobe, M.; Urabe, D.; Nishikawa, T. Angew. Chem. Int. Ed.
2004, 43, 4782-4785).
[0011] Also, Isobe has reported the synthesis of different unnatural analogues of Tetrodotoxin following similar strat-
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egies as those reported for Tetrodotoxin. Concretely, Isobe et al. has reported the synthesis of (-)- 5,11- Dideoxytetro-
dotoxin (Isobe, M.; Asai, M.; Ohyabu, N.; Yamamoto, N.; Nishikawa, T. Angew. Chem. Int. Ed. 1999, 38, 3081-3084),
(-)- 8,11-Dideoxytetrodotoxin (Isobe, M.; Asai, M.; Iwabuchi, T.; Yoshida, K.; Urabe, D.; Nishikawa, T. Org. Lett. 2002,
16, 2679-2682; Isobe, M.; Asai, M.; Iwabuchi, T.; Yoshida, K.; Urabe, D.; Nishikawa, T. Chem. Eur. J. 2004, 10, 452-462)
and 11-Deoxytetrodotoxin (Isobe, M.; Asai, Nishikawa, T. J. Am. Chem. Soc. 2002, 124, 7847-7852).
[0012] Sato et al. have recently reported an asymmetric total synthesis of Tetrodotoxin from myo- inositol in approxi-
mately 0.14% overall yield after 40 steps (Sato, K.; Akai, S.; Sugita, N.; Ohsawa, T.; Kogure, T.; Shoji, H.; Yoshimura,
J. J. Org. Chem. 2005, 70, 7496-7504).
[0013] Also, further discussions regarding different synthetic approaches to Tetrodotoxin and its analogues may be
reviewed in Koert, U. T. Angew. Chem. Int. Ed. 2004, 43, 5572-55769 .
[0014] Our copending patent application EP05077580.8 discloses a method for the preparation of TTX and derivate
thereof. Said synthesis comprises the rearrangement of a compound having the formula V to yield a compound of formula
VI
[0015] In view of all of the above there is an existing need of providing an alternative cost effective and efficient
synthesis of Tetradotoxin and analogues thereof, as well as intermediates therefor, which can be used for the industrial
production of sufficient amounts of these compounds. Further, it will open the way to new analogues with useful biological
and pharmacological properties.
SUMMARY OF THE INVENTION
[0016] The authors have found that the rearrangement of a spirolactam of formula I as described below in the presence
of an acid reagent, yields compounds of formula II, III or IV (further described bellow), which are useful intermediates
in the synthesis of TTX and analogues and derivatives thereof.
Thus, a first aspect of the present invention is a process for rearranging the spirolactam of a compound of formula I
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wherein
R1 is selected from the group consisting of-H, -OH and -OPr1;
R2 is selected from the group consisting of -H, -CH2OH and -CH2OPr2; or
R1 and R2 together are =O, substituted or unsubstituted alkenyl, -CH2-O-, or -O- Prcy-O-CH2-;
R3 is selected from the group consisting of -H, -OH, -OPr3 and =O;
R4 is selected from the group consisting of -H, cyano, substituted or unsubstituted alkyl, -OPrl4, -OPr4, -OH, sub-
stituted or unsubstituted alkenyl and substituted or unsubstituted alkynyl;
the dotted lines represent an optional additional bond;
if the additional bond is present then R5 is not present;
if the bond between C8 and C9 is a single bond, R5 is selected from the group consisting of -H, -OH and -OPr5; or
R4 and R5 together are =O; or
R3 and R5 or R3 and R2 together are -O-, forming an epoxide ring;
R6 is selected from -H, -OH, -OPrl6, -OPr6 and =O;
R7 is selected from the group consisting of -H, -OH, -OPr7 and =O; or
R7 and R6 together are -O- Prcy-O-;
Ra and Rb are each independently selected from the group consisting of -H, -OH, -OPrab, substituted or unsubstituted
alkyl, substituted or unsubstituted amino and halogen;
Pr1, Pr2, Pr3, Pr4, Pr5, Pr6, Pr7, Prcy and Prab, are, the same or different, hydroxyl protecting groups;
Prl6 and Prl4 are acid labile hydroxyl protecting groups;
W is selected from the group consisting of -H, substituted or unsubstituted alkyl, substituted or unsubstituted aryl,
substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclyl and substituted or unsubstituted alke-
nyl;
or its tautomers, salts or solvates thereof;
wherein
A) if R4 is -OH or -OPrl4 and the compound of formula I is reacted with an acid reagent, a compound of formula II
is formed
wherein R1, R2, R3, R6, R7, Ra, Rb and W are as defined in formula I; or its tautomers, salts or solvates thereof; or
B) if R6 is -OH or -OPrl6 and the compound of formula I is reacted with an acid reagent, a compound of formula III
is formed
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wherein R1, R2, R3, R4, R5, R7, Ra, Rb and W are as defined in formula I; or its tautomers, salts or solvates thereof; or
C) if R4 is not -OH or -OPrl4, and R6 is not -OH or -OPrl6, and the compound of formula I is reacted with an acid
reagent or with halogen hydride, a compound of formula IV is formed
wherein R1, R2, R3, R4, R5, R6, R7, Ra, Rb and W are as defined in formula I; or its tautomers, salts or solvates thereof
[0017] A further aspect of the invention is a compound of formula II as defined in above or its tautomers, salts or
solvates thereof.
[0018] A further aspect of the invention is a compound of formula III as defined in above or its tautomers, salts or
solvates thereof.
[0019] A further aspect of the invention is a compound of formula IV as defined in above or its tautomers, salts or
solvates thereof.
DETAILED DESCRIPTION OF THE INVENTION
Synthesis of compounds of formula II, III and IV
[0020] In their ongoing research effort to provide alternative methods for the synthesis of TTX and derivates thereof,
the authors found that, surprisingly, when either of R4 or R6 in a compound of formula I are deprotected hydroxyl groups
or protected hydroxyl groups with protective groups labile in acid media, deprotection of the hydroxyl group is followed
by cyclation in the same reaction media to efficiently yield the compounds of formula II or III, their tautomers, salts or
solvates thereof.
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[0021] Further, in the absence of deprotected hydroxyl groups or protected hydroxyl groups with acid labile protecting
groups in R4 and R6, the reaction follows an alternative route to yield a compound of formula IV. The same compound
of formula IV, its tautomers, salts or solvates thereof, may be obtained be reacting the compound of formula I with an
halogen hydride.
[0022] Thus, as mentioned in the summary of the invention, a first aspect of the present invention is a process for
rearranging the spirolactam of a compound of formula I as defined above to yield compounds of formula II, III or IV, its
tautomers, salts or solvates thereof.
[0023] For purposes of the present invention, the compounds of general formula I, II, III and IV have been numbered
as follows: 
[0024] The compound of formula I used as starting material may be readily obtained by the processes described in
our copending PCT Patent Applications PCT/EP2005/005146 and PCT/EP2005/005149 and European Patent Applica-
tions EP04380295.8 and EP05077580.8, which are herein incorporated by reference in their entirety.
[0025] The compounds of formula II, III and IV or their tautomers, salts or solvates thereof, obtained in the process of
the invention are useful intermediates in the synthesis of TTX and derivatives thereof. As mentioned above, the process
of the invention takes alternative routes depending on the nature of R4 and R6. Thus, according to an embodiment, the
process of the invention comprises reacting said compound of formula I, or its tautomers, salts or solvates thereof,
wherein R4 is selected from the group consisting of -OH and -OPrl4, and R1, R2, R3, R5, R6, R7, Ra, Rb and W are as
previously defined, with an acid reagent to yield said compound of formula II or its tautomers, salts or solvates thereof.
[0026] According to a further embodiment, the process of the invention comprises reacting said compound of formula
I, or its tautomers, salts or solvates thereof, wherein R6 is selected from the group consisting of -OH and -OPrl6, and
R1, R2, R3, R4, R5, R7, Ra, Rb and W are as previously defined, with an acid reagent to yield said compound of formula
III or their tautomers, salts or solvates thereof
[0027] According to a further embodiment, the process of the invention comprises reacting said compound of formula
I, or their tautomers, salts or solvates thereof, wherein R4 is not -OH or -OPrl4, R6 is not -OH or -OPrl6, and R1, R2, R3,
R5, R7, Ra, Rb and W are as previously defined, with an acid reagent or with a halogen hydride to yield said compound
of formula IV, or their tautomers, salts or solvates thereof.
[0028] In order to obtain the compounds of formula II or III it is necessary that either R4 or R6 are deprotected hydroxyl
groups or protected hydroxyl groups with groups labile in acid media. The skilled person is aware of the protecting groups
which are readily cleaved under acid conditions. For further reference of hydroxyl protecting groups which are cleaved
under acid conditions, see the reactivity charts present in pages 705-720 of Greene and Wuts’ "Protective Groups in
Organic Synthesis", John Wiley & Sons, Inc., New York, 3rd Edition, 1999. According to a preferred embodiment, Prl6
and Prl4 are independently selected from the group consisting of silyl ethers, preferably silyl ethers of formula -Si(R’)3,
such as trimethylsilyl ether (also represented as "TMS"), triethylsilyl ether, tert- butyldimethylsilyl ether (also represented
as "TBDMSO"), tert-butyldiphenylsilyl ether, tri-isopropylsilyl ether, diethylisopropylsilyl ether, thexyldimethylsilyl ether,
triphenylsilyl ether, di-tert-butylmethylsilyl ether; or esters of formula -C(=O) R’, such as acetate ester, benzoate ester;
pivalate ester; chloroacetate ester; levulinate ester; wherein R’ represents a substituent selected from the group consisting
of substituted of unsubstituted alkyl, substituted of unsubstituted alkenyl, substituted of unsubstituted alkynyl, substituted
of unsubstituted aryl and substituted of unsubstituted aralkyl
[0029] The reaction conditions and the acid reagent to be used for process of the invention depend on whether R4 or
R6 are protected or deprotected. If either of R4 or R6 is protected, the nature of the protecting group must also be
considered. According to a preferred embodiment, said acid reagent is selected form the group consisting of silyl triflates
(also represented as "Tf"), preferably TMSOTf , and diluted acids, preferably diluted sulphuric acid, diluted hydrochloric
acid or diluted acetic acid. "Diluted acid" makes reference to an acid with a concentration in solution bellow 20% wt,
preferably bellow 10% wt, more preferably bellow 5% wt.
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[0030] According to a preferred embodiment, said halogen hydride is sodium hydride. Further, in the synthesis of
complex natural products it is always advantageous to perform more than one reaction in a single synthetic step. The
skilled person is aware that a hydroxyl group reacts with hydrides to form hydrogen gas and the corresponding alcoxide
having a negative charge. Said alcoxide may further react with an electrophile. In fact, this is a common method used
to introduce protecting groups in hydroxyl moieties. Thus, according to a preferred embodiment, if any of R1, R2, R3,
R5, R7, Ra or Rb comprise a hydroxyl group, the process of the invention comprises reacting the compound of formula
I, its tautomers, salts or solvates thereof, with a halogen hydride and an electrophile. In this way it is possible to simul-
taneously rearrange the spirolactam moiety and protect one or more hydroxyl groups of the compound of formula I.
There are a number of electrophiles known in the art which are suitable. Reference is made to Greene and Wuts’
"Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1999. Electrophiles commonly used are
halides of formula R8X, wherein X is a halogen atom, and R8 is selected from the group consisting of substituted or
unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted
aralkyl, substituted or unsubstituted heterocyclyl, -C(O) R9, -C(O)OR9 and -C(O) NR9R10, wherein each of R9 and R10
is independently selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted hetero-
cyclyl.
[0031] The compounds of formula I, II, III and IV or their tautomers, salts or solvates thereof, may have vecinal hydroxyl
groups, allowing the simultaneous protection of two of them through the use of diol protecting groups if desired. Among
the diol protecting groups that can be used we have O,O- acetals such as isopropylidene acetals (acetonides); cyclohex-
ylidene and cyclopentylidene acetals; arylmethylene acetals; methylene acetals; diphenylmethylene acetals; 1,2- dia-
cetals such as dispiroketal (dispoke) derivatives, cyclohexane- 1,2-diacetals, butane-2,3-diacetals; silylene derivatives;
1,1,3,3- tetraisopropyldisiloxanylidene derivatives or N,O-acetals. Additional examples of diol protecting groups can be
found in reference books such as Greene and Wuts’ "Protective Groups in Organic Synthesis", John Wiley & Sons, Inc.,
New York, 1999. Additionally, borolanes can be formed on the two vicinal hydroxy groups, for example using phenylboric
acid. The use of protecting groups of a certain size, or that are linked simultaneously to two different positions can control
the stereochemistry of the product.
[0032] Further, it will be immediately apparent to the skilled person that a compound of formula I or its tautomers, salts
or solvates thereof, can be readily transformed into a compound having the same formula I through known reactions.
The same is true for the compounds of formula II, III and IV their tautomers, salts or solvates thereof. That is, a compound
of formula II can be further transformed into a compound having the same formula II or its tautomers, salts or solvates
thereof, a compound of formula III can be further transformed into a compound having the same formula III or its tautomers,
salts or solvates thereof, and a compound of formula IV can be further transformed into a compound having the same
formula IV or its tautomers, salts or solvates thereof. Said transformations are for example disclosed in our copending
applications mentioned above, and may be effected by applying a basic set of reactions selected from:
a) Hydroxilation, dihydroxylation or ketohydroxylation: using mild (such as OsO4/ N oxide amine) or strong systems
(such as RuCl3) depending on the position to be hydroxylated. Alternative systems are also envisaged.
b) Nucleophilic attack at the carbonyl group: for example with a carbanion on a sp, sp2 or sp3 C, the carbanion can
be prepared or generated in situ; or with an hydride. The Nucleophilic attack allows the introduction of new func-
tionalities, new carbonated structures and also epoxides or double bonds, depending on the reagents used.
c) Hydroxyl inversion : for example through epimerization or inversion, for example in Mitsunobu conditions.
d) Hydroxyl or carbonyl protection or deprotection: using the same or different protecting groups in conditions as
explained above.
e) Allylic rearrangements: allows migration of a double bond.
[0033] For example, a compound of formula I wherein R4 and R5 together are =O, may undergo triflation followed by
nucleophilic attack by cyanide. Alternatively, said carbonyl in C9 may be directly attacked by cyanide, optionally followed
by dehydration. The resulting compounds may be further used to obtain compounds of formula III or IV following the
process of the invention: 
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[0034] In our previous patent applications EP 04076477.1 and PCT/EP2005/005149 we devised different reaction
sequences in order to arrive to the correct structure of R1 and R2. The same reaction sequences can also be successfully
applied to compounds of formula I, II, III and IV of the invention. For example, introduction of C11 of TTX in a compound
of formula IV wherein R1 and R2 together are =O, can be performed in three different ways: 
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[0035] Also, double bonds present in any of the compounds of formula I, II, III or IV may undergo reactions such as
epoxidation, dihydroxylation or hydrogenation:
[0036] During the total synthesis of organic compounds it is some times necessary to change a protecting group at a
EP 1 889 840 A1
11
5
10
15
20
25
30
35
40
45
50
55
given position for different reasons. The present invention encompasses such transformations. The skilled person is
aware of the conditions under which it is necessary to exchange the hydroxyl protecting group or an amino protecting
group at a given time.
[0037] One of the characteristics of TTX is the presence of a guanidine moiety. Our co-pending patent application
EP05077580.8, discloses the possibility of introducing the guanidine moiety at an early stage in the synthesis. The same
strategy is also possible with the compounds of the present invention. Thus, any of the compounds of formula II, III or
IV may undergo a nitrogen deprotection reaction followed by reaction with a guanidine precursor: 
[0038] Wherein, X1 and X2 are independently selected from NH, O or S. Any of the hydrogen atoms attached to the
nitrogen atom in X1 or X2, may be replaced by an amino protecting as disclosed in our co-pending patent application
EP05077580.8. Alternatively, the guanidine precursor may be a compound of formula
wherein X2 has the same meaning as above; and X1 and X3 are independently selected from the group consisting of
-NH2, -OH, alkoxy, -OPr, -SH and -Salkyl. Any of the hydrogen atoms attached to the nitrogen atom in X1, X2 or X3, may
be replaced by an amino protecting as disclosed in our co-pending patent application EP05077580.8.
[0039] Additional examples of amino protecting groups can be found in reference books such as Greene and Wuts’
"Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1999.
[0040] A further feature of TTX is the presence of a hydroxyl group at C9, which may be introduced using conditions
known to the skilled person. For example, formation of the corresponding enolate followed by addition of oxaziridine to
a compound of formula I, II, III or IV results is the introduction of the hydroxyl group (see J. Org. Chem. 1992,
57,6387-6389). The hydroxyl group can then be protected with any desired hydroxyl protecting group.
[0041] The introduction of the hydroxyl group at C9 results in two possible diastereoisomers. Thus, the compounds
of formula I, II, III or IV having the opposite configuration at C9 with regard to TTX can be obtained as the mayor product.
These derivatives are also useful, since epimerization of different hydroxyl functional groups, including C9, throughout
the synthesis can be carried out under Mitsonobu conditions (Mitsunobu, 0.; Synthesis, 1, 1981)
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Compounds of formula II, III and IV
[0042] A further aspect of the invention is a compound of formula II as defined above or its tautomers, salts or solvates
thereof.
[0043] In order to obtain TTX and its derivatives, the compound of formula II, its tautomers, salts or solvates thereof,
is preferably one wherein R3 is -OH or -OPr3. According to a further embodiment R7 is -OH or -OPr7.
[0044] As mentioned above, in the synthesis of complex natural products it is always advantageous to perform more
than one reaction in a single synthetic step. Besides R4 or R6, either of R1, R2, R3, R5, R7, Ra or Rb may also be hydroxyl
protected groups. According to the process of the invention, the compound of formula I may be treated with an acid
reagent. If any of R1, R2, R3, R5, R7, Ra or Rb are a hydroxyl group protected, said hydroxyl protecting group will be
also cleaved if it is an acid labile hydroxyl protecting group. Thus, according to a preferred embodiment, at least one of
Pr1, Pr2, Pr3, Pr5, Pr7, Prcy, and Prab is an acid labile hydroxyl protecting group, preferably Pr3 or Pr7.
[0045] According to an embodiment, R7 and R6 together are -0- Prcy- O-.
[0046] According to a preferred embodiment, W in -CH2-Ph.
[0047] According to a preferred embodiment, the compound of formula II is a compound of formula IIb
wherein R1, R2, Ra, Rb and Prcy are as defined above; 
or its tautomers, salts or solvates thereof.
[0048] According to a preferred embodiment, the compound of formula II is selected from
- rac-(1R, 5R, 6S, 7S, 8S, 9R)- 5-(benzyloxyamino)-8-(benzoyloxymethyl)- 9-(tert-butyldimethylsilyloxy)-6,7,8- trihy-
droxy-6,7-O-(1,1,3,3-tetraisopropyldisiloxano-1,3-diyl)-2-oxabicyclo[4.3.0] nonan-3-one: 
or its enantiomers, tautomers, salts or solvates thereof; or
- rac-(1R, 5R, 6S, 7S, 8S, 9R)- 5-(benzyloxyamino)-8-(benzoyloxymethyl) - 6,7,8,9-tetrahydroxy -6,7-O-(1,1,3,3- tetrai-
sopropyldisiloxane-1,3-diyl)- 2- oxabicyclo[4.3.0]nonan- 3-one: 
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or its enantiomers, tautomers, salts or solvates thereof.
[0049] A further aspect of the invention is a compound of formula III as defined above or its tautomers, salts or solvates
thereof. According to a preferred embodiment, R3 is -OH or -OPr3. According to a further embodiment, R7 is -OH or
-OPr7. According to a further embodiment, W in -CH2-Ph.
[0050] According to a preferred embodiment, at least one of Pr1, Pr2, Pr3, Pr5, Pr7, Prcy and Prab is an acid labile
hydroxyl protecting group, preferably Pr3 or Pr7. According to a preferred embodiment the compound of formula III is a
compound of formula IIIb
wherein R1, R2, Ra, Rb and Pr7 are as defined above;
or its tautomers, salts or solvates thereof
[0051] According to a preferred embodiment, the compound of formula III is selected from the group consisting of
- rac-(1S,5R, 9S)-5-(benzyloxyamino)- 9-hydroxy-2- oxabicyclo [4.3.0]non-6-en-3,8- dione: 
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or its enantiomers, tautomers, salts or solvates thereof;
- rac-(1S,5R, 9S)-5-(benzyloxyamino)- 9-(tert-butyldimethylsilyloxy)- 2-oxabicyclo [4.3.0] non-6-en- 3,8-dione: 
or its enantiomers, tautomers, salts or solvates thereof;
- rac-(1S,5R, 9S)-5-(benzyloxyamino)- 9-(tert-butyldimethylsilyloxy)- 8-methylen-2-oxabicyclo[4.3.0]non- 6-en-3-one:
or its enantiomers, tautomers, salts or solvates thereof;
- rac-(1S,5R, 9S)-5-(benzyloxyamino)- 9-(tert-butyldimethylsilyloxy)- 8-hydroxy-8-hydroxymethyl-2-oxabicyclo [4.3.0]
non-6-en- 3-one: 
or its enantiomers, tautomers, salts or solvates thereof; and
- rac-(1S,5R, 9S)-5-(benzyloxyamino)- 9-(tert-butyldimethylsilyloxy)- 8-hydroxy-8-(tert-butyldimethylsilyloxymethyl)- 2-
oxabicyclo [4.3.0]non- 6-en-3- one: 
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or its enantiomers, tautomers, salts or solvates thereof.
[0052] A further aspect of the present invention is a compound of formula IV as defined above or its tautomers, salts
or solvates thereof.
[0053] According to a preferred embodiment, the compound of formula IV is a compound of formula IVb
wherein R1, R2, Prcy and W are as defined above;
or its enantiomers, tautomers, salts or solvates thereof.
[0054] According to a preferred embodiment, the compound of formula IV is selected from the group consisting of
- rac-(5R,6S, 7S,8R)- 1-benzyl- 6,7,8-trihydroxy- 8-[(4- methoxybenzyloxy) methyl] -6,7- O-(1,1,3,3-tetraisopropyldisi-
loxane-1,3- diyl)- 1-aza- 2- oxaspiro [4.5]dec- 9-en-3-one: 
or its enantiomers, tautomers, salts or solvates thereof;
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- rac-(5R,6S, 75,8R)-1- benzyl-6,7,8- trihydroxy-8-(hydroxymethyl)-6,7-O-(1,1,3,3- tetraisopropyldisiloxane-1,3-diyl)-
1-aza- 2-oxaspiro [4.5] dec-9- en- 3- one:
or its enantiomers, tautomers, salts or solvates thereof;
- rac-(5R, 6S, 7S)- 1- benzyl-6,7-dihydroxy- 6,7-O-(1,1,3,3,-tetraisopropyl disiloxane-1,3-diyl)-1-aza- 2-oxaspiro[4.5]
dec-9-en-3,8-dione: 
or its enantiomers, tautomers, salts or solvates thereof; and
- rac-(5R,6S, 7S)-6,7-dihydroxy-6,7- O-(1,1,3,3,-tetraisopropyldisiloxane- 1,3-diyl)-1- aza- 2-oxaspiro [4.5] dec- 9-en-
3,8- dione: 
or its enantiomers, tautomers, salts or solvates thereof
Definitions
[0055] In the definition of compounds disclosed herein and in the description, the following terms have the meaning
indicated:
"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms, con-
taining no saturation, having 1-12, preferably one to eight carbon atoms, and which is attached to the rest of the
molecule by a single bond, e. g., methyl, ethyl, n-propyl, i-propyl, n- butyl, t-butyl, n- pentyl, etc. Alkyl radicals may
be optionally substituted by one or more substituents such as halo, hydroxy, alkoxy, OPr, OBn, OBz, carboxy, cyano,
carbonyl, acyl, alkoxycarbonyl, amino, imino, nitro, mercapto and alkylthio.
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"Alkenyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms,
containing at least one unsaturation, having 1-12, preferably one to eight carbon atoms, and which is attached to
the rest of the molecule by a single bond or by a double bond, e.g. -CH=CH2, -CH=CHCH3, -CH2-(CH=CH)nCH3,
wherein n is an integer between 1 and 5, =CH2, =CHCH3. Alkenyl radicals may be optionally substituted by one or
more substituents such as halo, hydroxy, alkoxy, O-propyl, O- benzyl, O-benzoate, carboxy, cyano, carbonyl, acyl,
alkoxycarbonyl, amino, imino, nitro, mercapto and alkylthio.
"alkynyl" refers to a straight or branched hydrocarbon chain radical consisting of carbon and hydrogen atoms,
containing at least one carbon-carbon triple bond, conjugated of not, and which is attached to the rest of the molecule
by a single bond, such as -CCH, -CH2CCH, -CCCH3, -CH2CCCH3.
"Alkoxy" refers to a radical of the formula -ORa where Ra is an alkyl radical as defined above, e. g., methoxy,
ethoxy, propoxy, etc. "Aryloxy" refers to a radical of formula -ORb wherein Rb is an aryl radical as defined below.
"Amino" refers to a radical of the formula-NH2 , -NHRa, -NRaRb.
"Aryl" refers to an aromatic hydrocarbon radical such as phenyl (also represented as "Ph"), naphthyl or anthracyl.
The aryl radical may be optionally substituted by one or more substituents such as hydroxy, mercapto, halo, alkyl,
phenyl, alkoxy, haloalkyl, nitro, cyano, dialkylamino, aminoalkyl, acyl and alkoxycarbonyl, as defined herein.
"Aralkyl" refers to an aryl group linked to an alkyl group such as benzyl and phenethyl.
"Heterocyclyl" refers to a stable 3- to 15- membered ring which consists of carbon atoms and from one to five
heteroatoms selected from the group consisting of nitrogen, oxygen, and sulphur, preferably a 4- to 8-membered
ring with one or more heteroatoms, more preferably a 5-or 6-membered ring with one or more heteroatoms. For the
purposes of this invention, the heterocycle may be a monocyclic, bicyclic or tricyclic ring system, which may include
fused ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidised;
the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated or
aromatic. Examples of such heterocycles include, but are not limited to, azepines, benzimidazole, benzothiazole,
furan, isothiazole, imidazole, indole, piperidine, piperazine, purine, quinoline, thiadiazole, tetrahydrofuran.
"Amino" refers to a radical of the formula -NH2, -NHRa, -NRaRb, wherein Ra and Rb are independently selected
from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted cycloalkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl or
substituted or unsubstituted heterocyclyl; or Ra and Rb together form a substituted or unsubstituted heterocycle,
substituted or unsubstituted cycloalkyl or substituted or unsubstituted cycloalkenyl.
"halogen" refers to -F, -Cl, -Br or -I.
"Protecting group" refers to a group that blocks an organic functional group and can be removed under controlled
conditions. Protecting groups, their relative reactivity and conditions under which they remain inert are known to the
skilled person. Reference is made to Greene and Wuts "Protective Groups in Organic Synthesis", John Wiley &
Sons, Inc., New York, 1999.
"Hydroxyl protecting group" refers to a group that blocks the -OH function for further reactions and can be removed
under controlled conditions. The hydroxyl protecting groups are well known in the art, representative protecting
groups are: 
- silyl ethers of formula -Si (R’)3, such as trimethylsilyl ether (also represented as "TMS"), triethylsilyl ether, tert-
butyldimethylsilyl ether (also represented as "TBDMSO"), tert- butyldiphenylsilyl ether, tri-isopropylsilyl ether,
diethylisopropylsilyl ether, thexyldimethylsilyl ether, triphenylsilyl ether, di-tert-butylmethylsilyl ether;
- alkyl ethers of formula -R’, such as methyl ether, tert-butyl ether, benzyl ether, p-methoxybenzyl ether, 3,4-
dimethoxybenzyl ether, trityl ether; allyl ether;
- alkoxymethyl ethers of formula -CH2-O- R’, such as methoxymethyl ether, 2-methoxyethoxymethyl ether, ben-
zyloxymethyl ether, p- methoxybenzyloxymethyl ether, 2-(trimethylsilyl)ethoxymethyl ether. The oxygen atom
may be replaced by a sulphur atom to form an alkylthiomethyl ether of formula -CH2-S-R’, such as methylthi-
omethyl ether. Tetrahydropyranyl and related ethers are also commonly used as hydroxyl protecting groups;
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- esters of formula -C (=O) R’, such as acetate ester, benzoate ester; pivalate ester; methoxyacetate ester; chlo-
roacetate ester; levulinate ester;
- carbonates of formula -C(=O)-O- R’, such as benzyl carbonate, p- nitrobenzyl carbonate, tert- butyl carbonate,
2,2,2- trichloroethyl carbonate, 2-(trimethylsilyl)ethyl carbonate, allyl carbonate; or
- sulphates such as SO3.py.
[0056] In all the above formula R’ represents a group selected from the group consisting of substituted of unsubstituted
alkyl, substituted of unsubstituted alkenyl, substituted of unsubstituted alkynyl, substituted of unsubstituted aryl and
substituted of unsubstituted aralkyl.
[0057] Additional examples of hydroxyl protecting groups can be found in reference books such as Greene and Wuts’
"Protective Groups in Organic Synthesis", John Wiley & Sons, Inc., New York, 1999.
[0058] References herein to substituted groups in the compounds of the present invention refer to the specified
moiety that may be substituted at one or more available positions by one or more suitable groups, e. g., halogen such
as fluoro, chloro, bromo and iodo ; cyano; hydroxyl ; nitro ; azido ; alkanoyl such as a C1-C6 alkanoyl group such as acyl
and the like ; carboxamido ; alkyl groups including those groups having 1 to about 12 carbon atoms or from 1 to about
6 carbon atoms and more preferably 1-3 carbon atoms ; alkenyl and alkynyl groups including groups having one or more
unsaturated linkages and from 2 to about 12 carbon or from 2 to about 6 carbon atoms ; alkoxy groups having one or
more oxygen linkages and from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms ; aryloxy such as phenoxy ;
amino groups such as groups having one or more N atoms, optionally substituted with 1 or 2 alkyl groups having from
1 to about 12 carbon atoms or from 1 to about 6 carbon atoms ; carbocylic aryl having 6 or more carbons, particularly
phenyl or naphthyl and aralkyl such as benzyl. Unless otherwise indicated, an optionally substituted group may have a
substituent at each substitutable position of the group, and each substitution is independent of the other.
[0059] All the compounds will be obtained as racemic mixtures. However, if enantiopurity is desired, this can be
achieved by introducing a chiral center in the W group, introduncing different groups as Ra and Rb, or using chiral
reagents or catalysts. Therefore the compounds of the present invention may include pure enantiomers depending on
the presence of stereogenic centers or diastereoisomers. The single isomers, enantiomers or diastereoisomers and
mixtures thereof fall within the scope of the present invention. Mixtures of different diasteroisomers can be separated
by conventional techniques.
[0060] Unless otherwise stated, the compounds of the invention are also meant to include compounds which differ
only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures
except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by a 13C- or 14C-
enriched carbon or 15N- enriched nitrogen are within the scope of this invention.
[0061] The compounds of the invention may be in crystalline form either as free compounds or as solvates (e.g.
hydrates) and it is intended that both forms are within the scope of the present invention. Methods of solvation are
generally known within the art.
[0062] Further embodiments of the compounds of the invention are described below in the examples. It is evident for
the skilled person that many variations and configurations are possible and can be obtained at will depending on the
compounds selected as starting materials, the relative configurations of the functional groups present, the presence or
not of chiral centers, and on the combination of reactions that are applied. The present invention encompasses all such
variations (enantiomers and diastereoisomers) and possibilities.
EXAMPLES
General Methods and Materials
[0063] All reactions described below were carried out under argon atmosphere unless otherwise noted. The solvents
used were distilled and dried under argon atmosphere before use. All starting materials were purchased commercially
(Aldrich, Fluka and Merck) and used without further purification. Flash Chromatography was executed on columns loaded
with 230-400 mesh silica gel Merck. TLC was carried out on silica gel Merck (Kieselgel 60F-254).
[0064] Melting points (mp) were determined on a Reichert Microscopic Hot-Stage and are uncorrected. 1H and 13C
NMR spectra were measured on Varian Gemini-200, Varian Inova-300 and Varian Inova- 400 spectrometers with (CH3)4Si
as an internal reference and CDCl3 as solvent unless otherwise noted. Both 1H and 13C NMR spectral data are reported
in parts per million (δ) relative to residual signal of the solvent (CHCl3, 7.26 ppm and 77.0 ppm for 1H and 13C NMR,
respectively). 1H and 13C NMR designations are: s (singlete); br. s (broad singlete); d (doublete); br. d (broad doublete);
t (triplete); q (quartete); m (multiplete). Infrared (IR) spectra were record on a Perkin-Elmer FT-IR spectrometer. UV
spectra were record on a Perkin-Elmer 402 spectrometer. Low-resolution mass (LRMS) spectra were obtained on a
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Hewlett Packard 5973 MSD spectrometer with a direct inlet system (EI) at 70 eV.
Synthesis of compounds of formula II
Example 1: Preparation of rac-(4R, 5S, 6S, 7S, 8R, 9R)-1-benzyloxy-7-(benzoyl oxymethyl)- 8-(tert-butyldimethyl-
silyloxy)- 5,6,7,9-tetrahydroxy- 5,6-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)-l- azaspiro [3.5] nonan- 2-one (15) 
and rac-(1R, 5R, 6S, 7S, 8S, 9R)-5-(benzyloxyamino)- 8-(benzoyloxymethyl)-9-(tert-butyldimethylsilyloxy)- 
6,7,8-trihydroxy- 6,7-O-(1,1,3,3-tetraisopropyldisiloxano- 1,3-diyl)- 2-oxabicyclo [4.3.0] nonan- 3-one (16)
[0065]
[0066] To a solution of rac-(4R, 5S, 6S, 7S, 8R, 9R)- 1-benzyloxy-7-(benzoyloxymethyl)- 8-(tert-butyldimethylsilyloxy)-
5,6,7-trihydroxy- 5,6-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)-9-(trimethylsilyloxy)- 1-azaspiro[3.5] nonan-2-one (14)
(293 mg, 0.330 mmol) in 1% HCl (1.8 ml, 1 wt. % solution in EtOH, 0.495 mmol) was stirred at room temperature for 24
h. Then, 1% HCl solution in EtOH (1.8 ml) was added, and the mixture was stirred at room temperature until the reaction
was complete (24 h, TLC monitoring, hexane/ AcOEt, 2:1). The reaction was neutralized with 10% aqueous NaHCO3
solution and the mixture extracted with CH2Cl2 (3 x 3 ml). The combined extracts were dried over Na2SO4, filtered and
concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/AcOEt,
5: 1) to give rac-(4R,5S, 6S, 7S, 8R, 9R)- 1- benzyloxy- 7-(benzoyloxymethyl)-8-(tert- butyldimethylsilyloxy)-5,6,7,9-tetrahy-
droxy-5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro[3.5] nonan- 2-one (15) as a foamy white solid (250 mg,
93%), and rac-(1R, 5R,6S, 7S, 8S, 9R)- 5-(benzyloxyamino)-8-(benzoyloxymethyl)- 9-(tert- butyldimethylsilyloxy)-6,7,8-tri-
hydroxy-6,7-O-(1,1,3,3-tetraisopropyldisiloxano-1,3-diyl)-2-oxabicyclo [4.3.0]nonan-3-one (16) (15 mg, 6%), as a white
solid.
rac-(4R, 5S, 6S, 7S, 8R, 9R)- 1-benzyloxy- 7-(benzoyloxymethyl)- 8-(tert-butyldi methylsilyloxy)- 5,6,7,9-tetrahy-
droxy- 5,6-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)- 1-azaspiro[3.5]nonan-2-one (15)
[0067]
Rf = 0.51 (TLC, hexano/AcOEt, 2: 1), 0.17 (TLC, hexano/ AcOEt, 5:1); yield, 93%; white solid; m.p. = 87-89 °C; 1H- NMR
(300 MHz, CDCl3): δ 8.03 (2H, dm, J = 7.1 Hz, Bz), 7.62 (1H, tm, J = 7.3 Hz, Bz), 7.48 (2H, ddm, J = 7.3, 7.1 Hz, Bz),
7.45-7.35 (5H, m, Ph), 5.07 (1H, part A syst. AB, J = 11.4 Hz, OCH2Ph), 4.99 (1H, part B syst. AB, J = 11.4 Hz, OCH2Ph),
4.67 (1H, part A syst. AB, J = 11.6 Hz, H-10), 4.58 (1H, part B syst. AB, J = 11.6 Hz, H-10’), 4.52 (1H, d, J = 4.0 Hz, H-
5), 4,35 (1H, dd, J = 4.0, 0.9 Hz, H- 6), 4.03 (1H, dd, J = 3.4, 0.9 Hz, H- 8), 3.86 (1H, dd, J = 5.0, 3.4 Hz, H- 9), 2.98 (1H,
part A syst. AB, J = 14.1 Hz, H- 3), 2.89 (1H, part B syst. AB, J = 14.1 Hz, H-3’), 2.70 (1H, s, HO-C(7)), 1.62 (1H, d, J =
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5.0 Hz, HO-C(9)), 1.14-0.97 (28H, m, TIPDS), 0.87 (9H, s, C(CH3)3), 0.12 (3H, s, SiCH3), 0.07 (3H, s, SiCH3); 13C- NMR
(75 MHz, CDCl3): δ 168.4, 167.6, 136.2, 133.7, 129.6, 129.2, 128.9, 128.75, 128.7, 128.6, 78.5, 75.3, 74.9, 74.8, 69.8,
68.8, 67.9, 66.1, 34.8, 26.2, 18.5, 17.7, 17.65, 17.5, 17.3, 17.25, 17.2, 17.1, 17.0, 14.2, 14.0, 13.2, 13.0, -3.6, -5.5; IR
(film): v 3434, 2942, 2894, 2862, 1749, 1725, 1461, 1385, 1364, 1313, 1273, 1158, 1107, 1067, 997, 952, 912, 883,
832, 796, 778 cm-1; LRMS (API- ES+): m/z 1653 (2M+Na)+, 1631 (2M+H)+, 838 (M+Na)+, 816 (M+H)+.
rac-(1R, 5R, 6S, 7S, 8S, 9R)- 5-(benzyloxyamino)- 8-(benzoyloxymethyl)- 9-(tert- butyldimethylsilyloxy)- 6,7,8-trihy-
droxy- 6,7-O-(1,1,3,3-tetraisopropyldisiloxano- 1,3-diyl)- 2-oxabicyclo [4.3.0] nonan- 3-one (16)
[0068]
Rf = 0.36 (TLC, hexano/AcOEt, 5: 1), 0.64 (TLC, hexano/AcOEt, 2: 1); yield, 6%; white solid; 1H- NMR (300 MHz, CDCl3):
δ 8.02 (2H, dm, J = 7.2 Hz, Bz), 7.63 (1H, tm, J = 7.5 Hz, Bz), 7.48 (2H, ddm, J = 7.5, 7.2 Hz, Bz), 7.40-7.24 (5H, m,
Ph), 5:82 (1H, s, NH), 4.98 (1H, d, J = 5.3 Hz, H- 1), 4,93 (1H, d, J = 4.6 Hz, H- 6), 4.82 (1H, part A syst. AB, J = 12.0
Hz, OCH2Ph), 4.73 (1H, part B syst. AB, J = 12.0 Hz, OCH2Ph), 4.63 (2H, s, H- 10 and H- 10’), 4.47 (1H, d, J = 4.6 Hz,
H-7), 4,24 (1H, d, J = 5.3 Hz, H-9), 3.42 (1H, part A syst. AB, J = 16.9 Hz, H- 4), 2.71 (1H, s, OH), 1.85 (1H, part B syst.
AB, J = 16.9 Hz, H-4’), 1.20-0.95 (28H, m, TIPDS), 0.91 (9H, s, C(CH3)3), 0.21 (3H, s, SiCH3), 0.13 (3H, s, SiCH3); 13C-
NMR (75 MHz, CDCl3): δ 176.1, 167.3, 137.6, 133.7, 129.6, 129.1, 128.6, 128.3, 127.9, 127.7, 77.2, 76.8, 75.6, 73.5,
71.6, 67.9, 67.8, 67.5, 36.1, 25.9, 18.0, 17.65, 17.6, 17.5, 17.35, 17.3, 17.2, 17.1, 16.7, 13.9, 13.1, 12.7, 11.8, -4.2, -4.8;
IR (film): ν 3397, 2946, 2890, 2867, 1790 (shoulder), 1760, 1724, 1601, 1463, 1386, 1316, 1273, 1148, 1125, 1099,
1068, 997, 919, 883, 838, 778, 694 cm-1; LRMS (API- ES+): m/z 862 (M+2Na)+, 816 (M+H)+; LRMS (EI): m/z 758 (M+-
57, 7), 693 (1), 650 (1), 636 (2), 618 (1), 610 (1), 544 (1), 529 (1), 513 (2), 483 (3), 395 (2), 365 (5), 339 (17), 289 (6),
261 (8), 179 (9), 163 (4), 147 (5), 135 (6), 105 (100), 91 (76), 77 (8).
Example 2: Preparation of rac-(1R, 5R, 6S, 7S, 8S, 9R)- 5-(benzyloxyamino)- 8-(benzoyloxymethyl)-6,7,8,9-tetrahy-
droxy- 6,7-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-diyl)- 2-oxabicyclo [4.3.0]nonan-3-one (18)
[0069]
[0070] To a stirred solution of rac-(4R, 5S,6S, 7S, 8R, 9R)- 1-benzyloxy- 8,9-dihydroxy-5,6-(1,1,3,3- tetraisopropyldisi-
loxane- 1,3- diyl)- 10-(benzoyloxymethyl)-1- azaspiro[3.5] nonan-2- one (17) (50 mg, 0.071 mmol) in CH2Cl2 (1.5 ml) was
added at 0° C trimethylsilyl trifluoromethanesulfonate (16 Pl, 0.086 mmol). The resulting mixture was stirred at room
temperature until the reaction was completed (1h, TLC monitoring, hexane/AcOEt, 2:1). The reaction was quenched at
0° C with Na2PO4 0.1 M buffer until pH = 7 and the mixture extracted with CH2Cl2 (3 x 4 ml). The combined organic
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extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica
gel column chromatography (hexane- AcOEt, 3:1) to give rac-(1R, 5R, 6S, 7S, 8S, 9R)- 5-(benzyloxyamino)-8-(benzoy-
loxymethyl)-6,7,8,9- tetrahydroxy-6,7-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-2-oxabicyclo[4.3.0] nonan- 3-one (18)
(37 mg, 74%) as a white solid.
Rf = 0.37 (TLC, hexane/ AcOEt 2:1); yield, 74%; white solid; 1H- NMR (300 MHz CDCl3): d 8.04 (2H, d, J = 7.35 Hz,
OCOPh), 7.63 (1H, m, OCOPh), 7.48 (2H, m, OCOPh), 7.37-7.28 (5H, m, Ph), 5.72 (1H, br. s, NH), 4.97 (1H, d, J = 4.3
Hz, H- 6), 4.93 (1H, d, J = 4.7 Hz, H- 1), 4.88 (1H, part A syst. AB, J = 12.8 Hz, H-10), 4.81 (1H, part A syst. AB, J = 13.2
Hz, OCH2Ph), 4.73 (1H, part B syst. AB, J = 13.2, OCH2Ph), 4.73 (1H, part B syst. AB, J = 12.8 Hz, H-10’), 4.56 (1H,
d, J = 4.0 Hz, H-7), 4.20 (1H, dd , J = 8.6, 4.7 Hz, H- 9), 3.75 (1H, d, J = 8.6 Hz, OH), 3.28 (1H, br. s, OH), 3.06 (1H, part
A syst. AB, J = 17.7 Hz, H-4), 1.94 (1H, part B syst. AB, J = 17.7 Hz, H- 4’), 1.09-0.99 (28H, m, TIPDS); 13C- NMR (100
MHz, CDCl3): 175.8, 167.9, 137.3, 133.9, 129.8, 128.9, 128.65, 128.58, 128.4, 128.1, 127.8, 78.0, 74.8, 74.0, 71.1,
68.2, 67.8, 97.6, 36.5, 17.52, 17.48, 17.26, 17.21, 17.1, 17.0, 13.9, 13.4, 13.0, 12.7. IR (KBr): ? 3462, 3062, 3028, 2946,
2868, 1765, 1725, 1601, 1583, 1494, 1464, 1453, 1385, 1314, 1273, 1145, 1098, 1068, 1000, 885, 755, 698 cm-1; LMRS
(API-ES+): m/z 1425 (2M+Na)+, 792 (M+Na+H)+, 705 (M+4H)+, 704 (M+3H)+, 703 (M+2H)+, 702 (M+H)+.
Synthesis of compounds of formula III
Example 3: Preparation of rac-(1S, 5R, 9S)- 5-(benzyloxyamino)- 9-hydroxy- 2-oxabicyclo [4.3.0]nona- 6-en-3,8-di-
one (12) and/or rac-(1S, 5R, 9S)- 5-(benzyloxyamino)- 9-(tert-butyldimethylsilyloxy)-2-oxabicyclo [4.3.0]non-6-en- 
3,8-dione (13)
[0071]
Procedure A
[0072] To a stirred solution of rac-(4R, 5S, 6S)- 1-benzyloxy-5,6-dihidroxy-1-azaspiro[3.5]non-8-en-2,7-dione (9) (100
mg, 0.346 mmol) in CH2Cl2 (3 ml) at 0° C was added trimethylsilyl trifluoromethanesulfonate (76 Pl, 0.414 mmol). The
resulting mixture was stirred at room temperature until the reaction was complete (4.5 h, TLC monitoring, hexane/AcOEt,
1: 5). The reaction was quenched at room temperature with NaHCO3 solution. The layers were separated and aqueous
phase was extracted with CH2Cl2 (3 x 4 ml). The combined organic extracts were dried over Na2SO4, filtered and
concentrated under reduced pressure to give rac-(1S, 5R, 9S)- 5-(benzyloxyamino)-9- hydroxy-2-oxabicyclo[4.3.0] non- 6-
en-3,8-dione (12) (20 mg, 20%) as a colourless oil.
Procedure B
[0073] To a stirred solution of rac-(4R, 5S, 6S)- 1-benzyloxy-6-tert-butyldimethylsilyloxy-5-hydroxy- 1-azaspiro [3.5] non-
8-en-2,7- dione (10) (100 mg, 0.248 mmol) in CH2Cl2 (2.5 ml) was added at 0° C trimethylsilyl trifluoromethane-sulfonate
(54 Pl, 0.297 mmol). The resulting mixture was stirred at room temperature until the reaction was complete (10.5 h, TLC
monitoring, hexane/AcOEt, 1:1). The reaction was quenched at 0° C with Na2PO4 0.1 M buffer until pH = 7 and the
mixture extracted with CH2Cl2 (3 x 4ml). The combined organic extracts were dried over Na2SO4, filtered and concentrated
under reduced pressure. The residue was purified by silica gel column chromatography (hexane/AcOEt, 3: 1) to give
rac- (1S, 5R, 9S)- 5-(benzyloxyamino)-9-hydroxy-2- oxabicyclo [4.3.0] non-6- en- 3,8-dione (12) (21 mg, 28%), as a colour-
less oil, and rac-(1S, 5R,9S)- 5-(benzyloxyamino)-9-(tert-butyldimethylsilyloxy)- 2-oxabicyclo [4.3.0] non-6-en-3,8-dione
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(13) (70 mg, 70%), as a white solid.
Procedure C
[0074] To a stirred solution of rac- (4R, 5S, 6S)- 1-benzyloxy- 6-tert-butyldimethylsilyloxy-5-trimethylsilyloxy-1-azaspiro
[3.5] non-8-en-2,7-dione (11) (100 mg, 0.210 mmol) in CH2Cl2 (2 ml) was added at 0° C trimethylsilyl trifluoromethanesul-
fonate (48 Pl, 0.252 mmol). The resulting mixture was stirred at room temperature until the reaction was complete (20
h, TLC monitoring, hexane/AcOEt, 2: 1). The reaction was quenched at room temperature with saturated NaHCO3 solution
(1 ml). The layers were separated and aqueous phase was extracted with CH2Cl2 (3 x 4 ml). The combined organic
extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica
gel column chromatography (hexane/AcOEt, 4:1) to give rac- (1S, 5R, 9S)- 5-(benzyloxyamino)- 9-hydroxy- 2-oxabicyclo
[4.3.0]non-6-en-3,8-dione (12) (12 mg, 20%), as a colourless oil, and rac- (1S, 5R, 9S)- 5-(benzyloxyamino)-9-(tert-butyld-
imethylsilyloxy)- 2- oxabicyclo [4.3.0]non- 6-en- 3,8-dione (13) (44 mg, 52%), as a white solid.
rac-(1S, 5R, 9S)-5-(benzyloxyamino)- 9-hydroxy-2-oxabicyclo [4.3.0] non- 6-en-3,8-dione (12)
[0075]
Rf = 0.25 (TLC, hexane/AcOEt, 1: 1); yield, 20% (Procedure A), 28% (Procedure B), 20% (Procedure C); colourless
oil; 1H- NMR (300 MHz CDCl3): d 7.42-7.30 (5H, m, Ph), 6.44 (1H, part A syst. AB, J = 10.3, 2.2 Hz, H- 6 or H-7), 6.25
(1H, part B syst. AB, J = 10.3 Hz, H-7 or H- 6), 5.69 (1H, br. s, NH), 4.95 (1H, dd, J=3.4,2.2 Hz,H-1 or H- 9), 4.72 (3H,
m, OCH2Ph and H- 9 or H- 1), 3.47 (1H, br. s, OH), 2.95 (1H, part A syst. AB, J = 17.2 Hz, H-4), 2.50 (1H, part B syst.
AB, J = 17.2 Hz, H- 4’); 13C- NMR (75 MHz, CDCl3): d 195.2, 171.3, 145.1, 136.3, 128.8, 128.7, 128.6, 128.5, 128.4,
128.1, 82.4, 77.4, 71.8, 64.8, 60.3, 39.1; IR (film): ? 3429, 3246, 3062, 3033, 2926, 2872, 1790, 1704, 1494, 1453, 1375,
1246, 1219, 1143, 1045, 986, 918, 867, 832, 752, 700.5 cm-1 ; LMRS (API- ES+): m/z 601 (2M+Na)+, 312 (M+Na)+, 291
(M+2H)+, 290 (M+H)+.
rac-(1S, 5R, 9S)- 5-(benzyloxyamino)- 9-(tert-butyldimethylsilyloxy)-2-oxabicyclo [4.3.0] non-6-en-3,8-dione (13)
[0076]
Rf = 0.60 (TLC, hexane/ AcOEt, 1: 1); yield, 70% (Procedure B), 52% (Procedure C); white solid; m.p.: 111-113°C; 1H-
NMR (200 MHz CDCl3): d 7.42-7.22 (5H, m, Ph), 6.71 (1H, part A syst. AB, J = 10.3 Hz, H- 6), 6.13 (1H, part B syst.
AB, J = 10.3 Hz, H-7), 5.42 (1H, br. s, NH), 4.73 (1H, d, J = 3.7 Hz, H- 1), 4.69 (2H, s, OCH2Ph), 4.35 (1H, d, J = 3.7 Hz,
H-9), 2.78 (1H, part A syst. AB, J = 17.4 Hz, H-4), 2.48 (1H, part B syst. AB, J = 17.4 Hz, H- 4’), 0.83 (9H, s, C(CH3)3),
0.10 (3H, s, SiCH3), 0.08 (3H, s, SiCH3); 13C- NMR (50 MHz, CDCl3): d 194.7, 173.4, 145.8, 136.4, 128.7, 128.65, 128.6,
128.4, 80.3, 77.6, 73.3, 63.8, 38.3, 25.5, 18.1, -5.2, -5.3; IR (film): ? 3239, 2949, 2929, 2855, 1790, 1708, 1471, 1461,
1411, 1367, 1300, 1256, 1159, 1113, 1043, 989, 907, 837, 783, 750 cm-1; LMRS (API-ES+): m/z 829 (2M+Na)+, 807
(2M+H)+, 426 (M+Na)+, 404 (M+H)+.
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Example 4: Preparation of rac-(1S, 5R, 9S)-5-(benzyloxyamino)-9-(tert- butyldimethylsilyloxy)-8-methylen-2-ox-
abicyclo [4.3.0]non-6-en- 3-one (19)
[0077]
[0078] To a stirred suspension of methyltriphenylphosphonium (98 mg, 0.267 mmol) in THF (3 ml) was added dropwise
at -78 °C n-butyl lithium (0.17 ml, 1.6 M solution in hexane, 0.267 mmol) and the resulting light yellow solution was stirred
for 15 min at this temperature. Then, a solution of rac-(1S, 5R, 9S)- 5-(benzyloxyamino)-9-(tert- butyldimethylsilyloxy)- 2-
oxabicyclo [4.3.0]non- 6- en- 3,8- dione (13) (98 mg, 0.243 mmol) in THF (2 ml) was added dropwise and the mixture was
stirred for 2.5 h at room temperature. The reaction was concentrated under reduced pressure. The residue was purified
by silica gel column chromatography (hexane/ AcOEt, 4:1) to give rac-(1S, 5R, 9S)- 5-(benzyloxyamino)-9-(tert-butyld-
imethylsilyloxy)- 8- methylen-2- oxabicyclo [4.3.0]non-6-en-3- dione (19) (33 mg, 36%) as a colourless oil. 
Rf = 0.55 (TLC, hexane/ AcOEt, 2:1); yield, 36%; colourless oil; 1H- NMR (300 MHz CDCl3): d 7.35-7.29 (5H, m, Ph),
6.26 (1H, part A syst. AB, J = 10 Hz, H-7), 5.70 (1H, part B syst. AB, J = 10 Hz, H-6), 5.31 (1H, br. s, NH), 4.23 (1H, s,
H-10), 5.19 (1H, s, H- 10’), 4.70 (2H, s, OCH2Ph), 4.54 (2H, m, H-1 and H-9), 2.69 (1H, part A syst. AB, J = 17.2 Hz, H-
4), 2.50 (1H, part B syst. AB, J = 17.2 Hz, H-4’), 0.85 (9H, s, C(CH3)3), 0.10 (3H, s, SiCH3), 0.06 (3H, s, SiCH3); 13C-
NMR (75 MHz, CDCl3): d 175.0, 141.2, 136.9, 129.0, 128.5, 128.4, 128.1, 127.6, 117.0, 81.5, 77.5, 76.7, 71.6, 64.3,
38.5, 25.6, 18.0, -4.9, -5.0 ; IR (film): ? 3379, 3242, 3080, 3063, 3027, 2949, 2929, 2890, 2854, 1784, 1459, 1471, 1453,
1360, 1255, 1108, 1041, 891, 838, 778 cm-1; LMRS (API- ES+): m/z 601 (2M+Na)+, 312 (M+Na)+, 291 (M+2H)+, 290
(M+H)+.
Example 5: Preparation of rac- (1S, 5R, 9S)- 5-(benzyloxyamino)-9-(tert- butyldimethylsilyloxy)-8-hydroxy-8-hy-
droxymethyl-2-oxabicyclo [4.3.0]non- 6-en- 3-one (20)
[0079]
[0080] To a solution of rac-(1S, SR, 9S)- 5-(benzyloxyamino)-9-(tert- butyldimethylsilyloxy)-8-methylen-2-oxabicyclo
[4.3.0]non-6-en-3- one (19) (127 mg, 0.316 mmol) in acetone (1.5 ml) was added sequentially, at room temperature,
water (0.3 ml), N-methylmorpholine N-oxide (169 mg, 1.392 mmol) and osmium tetroxide (0.48 ml, 2.5 wt. % solution
in 2-methyl-2-propanol, 0.038 mmol). The resulting mixture was stirred at room temperature until the reaction was
complete (4 h, TLC monitoring, hexane/ AcOEt, 1: 1), and then quenched with 10% aqueous Na2S2O3 solution (0.2 ml).
After 15 min, the mixture was extracted with AcOEt (5 x 4 ml). The combined organic extracts were dried over Na2SO4,
filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/
AcOEt, 2: 1) to give rac-(1S, 5R, 9S)- 5-(benzyloxyamino)-9-(tert-butyldimethylsilyloxy)-8-hydroxy-8-hydroxymethyl-2-ox-
abicyclo [4.3.0]non- 6-en- 3- one (20) (90 mg, 66%) as a colourless oil.
Rf = 0.26 (TCL hexane/ AcOEt, 1:1); yield, 66%; colourless oil; 1H-NMR (300 MHz CDCl3): d 7.40-7.29 (5H, m, Ph),
5.90 (1H, part A syst. AB, J = 9.9 Hz, H-6 or H-7), 5.75 (1H, part B syst. AB, J = 9.9 Hz, H-7 or H-6), 5.37 (1H, br. s,
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NH), 4.91 (1H, d, J = 3.4 Hz, H-1 or H-9), 4.73 (1H, part A syst. AB, J = 11.3 Hz, OCH2Ph), 4.69 (1H, part B syst. AB,
J = 11.3 Hz, OCH2Ph), 4.20 (1H, d, J = 3.4, H-9 or H- 1), 3.80 (1H, part A syst. AB, J = 11.2, 4.6 Hz, H-10), 3.50 (1H,
part B syst. AB, J = 11.2, 8.0 Hz, H- 10’), 2.80 (1H, br. s, OH), 2.56 (1H, part A syst. AB, J = 17.6 Hz, H-4), 2.49 (1H,
part B syst. AB, J = 17.6 Hz, H- 4’), 2.29 (1H, dd, J = 8.0, 4.6 MHz, OH), 0.86 (9H, s, C(CH3)3), 0.14 (3H, s, SiCH3), 0.12
(3H, s, SiCH3); 13C- NMR (100 MHz, CDCl3): d 174.2, 136.2, 130.8, 130.3, 128.8, 128.6, 128.4, 80.4, 77.6, 77.2, 72.3,
72.0, 66.2, 63.8, 38.4, 25.8, 17.9, -4.4, -4.9; IR (film): ? 3435, 3027, 2950, 2926, 2884, 2854, 1775, 1494, 1453, 1402,
1361, 1258, 1100, 1052, 839 cm-1 ; LMRS (API-ES+): m/z 894 (2M+Na)+, 458 (M+Na)+, 459 (M+Na+H)+, 436 (M+H)+.
Example 6: Preparation of rac-(1S, 5R, 9S)-5-(benzyloxyamino)-9-(tert butyldimethylsilyloxy)- 8-hydroxy- 
8-(tert-butyldimethylsilyloxymethyl)- 2-oxabicyclo [4.3.0] non- 6-en- 3-one (21)
[0081]
[0082] To a solution of rac-(1S, 5R, 9S)- 5-(benzyloxyamino)- 9-(tert- butyldimethylsilyloxy)- 8-hydroxy-8- hydroxymethyl-
2-oxabicyclo [4.3.0] non- 6-en- 3 -one (20) (66 mg, 0.152 mmol) and imidazole (26 mg, 0.364 mmol) in DMF (0.8 ml) was
added at 0 °C a solution of tert-butyldimethylsilyl chloride (58 mg, 0.364 mmol) in DMF (0.7 ml). After 26 h at room
temperature, the reaction was quenched with H2O (3 ml) and the mixture extracted with AcOEt (3 x 5 ml). The combined
extracts were washed with saturated aqueous CuSO4 solution (3x10 ml) and brine (2x10 ml), dried over Na2SO4, filtered
and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/
AcOEt, 6: 1) to give rac-(1S,5R, 9S)- 5-(benzyloxyamino)- 9-(tert-butyldimethylsilyloxy)- 8-hydroxy- 8-(tert-butyldimethyls-
ilyloxymethyl)-2-oxabicyclo[4.3.0] non- 6-en-3- one (21) (76 mg, 91%) as a colourless oil. 
Rf = 0.44 (TLC, hexane/ AcOEt 3:1); yield, 91%; colourless oil; 1H- NMR (300 MHz CDCl3): d 7.35-7.28 (5H, m, Ph),
5.88 (1H, part A syst. AB, J = 10.5 Hz, H-6 or H-7), 5.82 (1H, part B syst. AB, J = 10.5 Hz, H-7 or H- 6), 5.36 (1H, br. s,
NH), 4.86 (1H, d, J = 3.4 Hz, H-1 or H-9), 4.74 (1H, part A syst. AB, J = 11.7 Hz, OCH2Ph), 4.69 (1H, part B syst. AB,
J = 11.7 Hz, OCH2Ph), 4.10 (1H, d, J = 3.4, H-9 or H- 1), 3.70 (1H, part A syst. AB, J = 9.8 Hz, H-10), 3.58 (1H, part B
syst. AB, J = 9.8 Hz, H-10’), 2.88 ( 1H, br.s, OH), 2.58 (1H, part A syst. AB, J = 17.3 Hz, H-4), 2.52 (1H, part B syst.
AB, J = 17.3 Hz, H-4’), 0.92 (9H, s, C(CH3)3), 0.84 (9H, s, C (CH3)3), 0.13 (3H, s, SiCH3), 0.10 (3H, s, SiCH3), 0.09 (3H,
s, SiCH3), 0.07 (3H, s, SiCH3).
Synthesis of compounds of formula IV
Example 7: Preparation of rac-(5R, 6S, 7S)-1-benzyl-6,7-dihydroxy-6,7-O-(1,1,3,3-tetraisopropyldisiloxane-
1,3-diyl)-1-aza-2-oxaspiro [4.5]dec- 9-en-3,8-dione (22) and rac-(5R, 6S, 7S)-6,7-dihydroxy-6,7-O-(1,1,3,3,-tetrai-
sopropyldisiloxane- 1,3-diyl)- 1-aza-2-oxaspiro [4.5]dec-9-en-3,8-dione (23)
[0083]
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[0084] To a stirred solution of rac-(4R,5S, 6S)- 1-benzyloxy-5,6-dihidroxy-5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-
diyl)-1-azaspiro[3.5]non- 8- en- 2,7-dione (1) (100 mg, 0.188 mmol) in CH2Cl2 (3 ml) at 0° C was added trimethylsilyl
trifluoromethanesulfonate (41.3 Pl, 0.226 mmol). The resulting mixture was stirred at room temperature until the reaction
was complete (17 h, TLC monitoring, hexane/AcOEt, 5:1, x4). The reaction was concentrated under reduced pressure.
The residue was purified by silica gel column chromatography (hexane/AcOEt, 6:1) to give rac-(5R, 6S, 7S)- 1-benzyl-
6,7- dihydroxy- 6,7-O-(1,1,3,3,-tetraisopropyldisiloxane-1,3-diyl)-1- aza-2-oxaspiro[4.5]dec-9-en-3,8-dione (22) (15 mg,
14%) and rac-(5R, 6S, 7S)-6,7-dihydroxy-6,7-O-(1,1,3,3,-tetraisopropyldisiloxane-1,3-diyl)-1-aza- 2-oxaspiro [4.5] dec- 9-
en-3,8-dione (23) (10 mg, 12%), both as an oils.
rac-(5R, 6S, 7S)- 1-benzyl- 6,7-dihydroxy-6,7-O-(1,1,3,3; tetraisopropyldisiloxane- 1,3-diyl)-1-aza- 2-oxaspiro [4.5]
dec- 9-en-3,8-dione (22)
[0085]
Rf = 0.5 (TLC, hexane/ AcOEt, 2: 1); yield, 14%; oil; 1H-NMR (300 MHz CDCl3): d 7.34 (5H, m, Ph), 6.67 (1H, part A
syst. AB, J = 10.3 Hz, H-9), 6.13 (1H, part A syst. AB, J = 10.3 Hz, H-10), 5.09 (1H, br. s, H- 6 or H- 7), 4.54 (1H, br. s,
H-7 or H-6), 4.30 (1H, d, part A syst. AB, J = 13.5 Hz, OCH2Ph), 4.10 (1H, part B syst. AB, J = 13.5 Hz, OCH2Ph), 3.46
(1H, J =17.7 Hz, H-4), 2.91 (1H, J = 17.7 Hz, H-4’), 1.26-0.99 (28H, m, TIPDS); 13C- NMR (100 MHz, CDCl3): d 194.6,
174.2, 135.5, 131.5, 129.45, 129.0, 128.9, 128.7, 128.6, 128.5, 128.4, 77.5, 75.9, 71.3, 58.5, 37.3, 17.8, 17.7, 17.5,
17.4, 17.2, 17.1, 14.4, 13.7, 13.0; IR (film): ? 3430, 2946, 2890, 2866, 1784, 1718, 1627, 1461, 1251, 1185, 1133, 1009,
923, 886, 749, 697 cm-1; LMRS (API-ES+): m/z 1085 (2M+Na)+, 555 (M+Na+H)+, 554 (M+Na)+, 534 (M+3H)+, 533
(M+2H)+, 532 (M+H)+; LMRS (EI): m/z 488 (34), 444 (25), 409 (16), 383 (12), 339 (21), 254 (6), 229 (14), 209 (4), 184
(6), 147 (9), 135 (14), 119 (13), 106 (28), 91 (100), 77 (2), 65 (4).
rac-(5R, 6S, 7S)- 6,7-dihydroxy-6,7-O-(1,1,3,3,-tetraisopropyldisiloxane-1,3-diyl)-1-aza-2-oxaspiro [4.5] dec-9-en-
3,8-dione (23)
[0086]
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Rf = 0.25 (TLC, hexane/AcOEt, 2: 1); yield, 12%; oil; 1H- NMR (300 MHz CDCl3): d 6.88 (2H, br. s, NH and H-8 or H- 9),
6.14 (1H, d, J = 10.2 Hz, H-9 or H- 8), 4.83- 4.72 (1H, br. s, H-6 or H- 7), 4.38 (1H, br. s, H- 7 or H- 6), 3.44 (1H, d, part A
syst. AB, J = 18.4 Hz, H-4), 2.67 (1H, part B syst. AB, J = 18.4 Hz, H-4’), 1.26-1.00 (28H, m, TIPDS); 13C- NMR (100
MHz, CDCl3): d 193.8, 176.7, 137.9, 128.5, 75.4, 67.1, 37.2, 17.4, 17.3, 17.2, 17.1, 17.0, 13.9, 13.2, 12.7, 2.0; IR (film): ?
3435, 3228, 2947, 2890, 2869, 1793, 1707, 1465, 1251, 1185, 1141, 1095, 1020, 923, 885, 699 cm-1; LMRS (API-ES+):
m/z 465 (M+Na+H)+, 464 (M+Na)+, 442 (M+H)+. LMRS (EI): m/z 441 (M+, 2), 409 (19), 398 (55), 370 (10), 354 (100),
339 (8), 327 (8), 308 (6), 295 (3), 259 (6), 235 (18), 207 (21),193 (17), 175 (19), 164 (35), 147 (28),135 (56), 119 (48),
105 (30), 91 (14), 77 (7), 65 (9).
Example 8: Reaction of rac-(4R, 5S, 6S, 7R)- 1-benzyloxy- 5,6,7-trihydroxy- 7-(hydroxymethyl)-
5,6-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-azaspiro [3.5]non-8-en-2-one (24), 4-methoxybenzyl chloride 
and sodium hydride
[0087]
[0088] To a solution of rac- (4R, 5S, 6S, 7R)- 1-benzyloxy- 5,6,7- trihydroxy- 7-(hydroxymethyl)-5,6-O-(1,1,3,3-tetraiso-
propyldisiloxane-1,3-diyl)- 1- azaspiro[3.5]non- 8-en-2- one (24) (76 mg, 0.135 mmol) in dry DMF (0.4 ml) was added at 0
°C NaH (7 mg, 0.162 mmol), the mixture was stirred for 30 min and then was added 4-methoxybenzyl chloride (24 Pl,
0.175 mmol) and the resulting mixture was stirred at room temperature. After 2.5 h, the reaction was quenched with cold
water (1 ml) and saturated aqueous NH4Cl solution (2 ml). The mixture was extracted with CH2Cl2 (3 x 2 ml). The
combined organic extracts were washed with H2O (2 ml), dried over Na2SO4, filtered and concentrated under reduced
pressure. The residue was purified by silica gel column chromatography (hexano/AcOEt, 6:1) to give rac-(5R, 6S, 7S,
8R)- 1-benzyl- 6,7,8-  trihydroxy- 8-(hydroxymethyl)-6,7-O-(1,1,3,3- tetraisopropyldisiloxane- 1,3-diyl)- 1-aza- 2-oxaspiro
[4.5] dec- 9- en- 3- one (25) (14 mg, 18%), as a white solid, rac-(5R, 6S, 7S, 8R)- 1- benzyl- 6,7,8-trihydroxy- 8-[(4- methoxy-
benzyloxy)methyl]-6,7-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-1-aza- 2- oxaspiro [4.5]dec- 9-en-3-one (26) (6 mg,
6%), as a yellow oil, and diol 24 (19 mg, 25%).
rac- (5R, 6S, 7S, 8R)- 1-benzyl- 6,7,8-trihydroxy-8-(hydroxymethyl)-6,7-O-(1,1,3,3-tetraisopropyldisiloxane- 1,3-di-
yl)-1-aza- 2-oxaspiro [4.5]dec- 9-en-3-one (25)
[0089]
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Rf = 0.19 (TLC, hexano/ AcOEt, 3: 1), 0.45 (TLC, hexano/AcOEt, 1:1); yield, 18%; white solid; 1H- NMR (200 MHz, CDCl3):
δ 7.33 (5H, br. s, Ph), 6.05 (1H, part A syst. AB, J = 9.9 Hz, H-10), 5.45 (1H, part B syst. AB, J = 9.9 Hz, H- 9), 4.88 (1H,
d, J = 3.5 Hz, H- 6), 4.71 (2H, s, NCH2Ph), 4.29 (1H, d, J = 3.5 Hz, H-7), 4.03 (1H, part A syst. AB, J = 11.3 Hz, H- 11),
3.58 (1H, part B syst. AB, J = 11.3 Hz, H-11’), 2.63 (1H, br. s, OH), 2.62 (1H, part A syst. AB, J = 17.4 Hz, H-4), 2.43
(1H, part B syst. AB, J = 17.4 Hz, H- 4’), 1.58 (1H, br. s, OH), 1.16-0.88 (28H, m, TIPDS); 13C-NMR (75 MHz, CDCl3):
δ 175.5, 136.9, 132.1, 128.7, 128.4, 128.1, 126.5, 79.6, 77.7, 72.6, 70.0, 65.4, 63.6, 38.4, 17.4, 17.3, 17.25, 17.2, 17.1,
17.0, 13.3, 13.1, 12.8, 12.75; IR (film): ν 3405, 2945, 2862, 1787, 1655, 1511, 1461, 1383, 1355, 1244, 1147, 1111,
1060, 1033, 919, 883 cm-1; LRMS (API- ES+): m/z 1149 (2M+Na)+, 1127 (2M+H)+, 586 (M+Na)+, 564 (M+H)+, 546 (M-
17)+.
rac- (5R, 6S, 7S, 8R)- 1-benzyl- 6,7,8-trihydroxy-8-[(4-methoxybenzyloxy) methyl]- 6,7-O-(1,1,3,3-tetraisopropyldis-
iloxane- 1,3-diyl)- 1-aza-2-oxaspiro [4.5] dec-9-en-3-one (26)
[0090]
Rf = 0.36 (TLC, hexano/ AcOEt, 3:1), 0.73 (TLC, hexano/ AcOEt, 1: 1); yield, 6%; yellow oil; 1H- NMR (200 MHz, CDCl3):
δ 7.41-7.28 (5H, m, Ph), 7.21 (2H, d, J = 8.6 Hz, p- CH3OC6H4), 6.84 (2H, d, J = 8.6 Hz,p-CH3OC6H4), 5.85 (1H, part A
syst. AB, J = 10.0 Hz, H- 9 or H- 10), 5.60 (1H, part B syst. AB, J = 10.0 Hz, H-10 or H- 9), 4.94 (1H, d, J = 3.4 Hz, H-6 or
H-7), 4.69 (2H, s, NCH2Ph), 4.68 (1H, part A syst. AB, J = 8.6 Hz, OCH2Ar), 4.58 (1H, part B syst. AB, J = 8.6 Hz,
OCH2Ar), 4.01 (1H, s, H-7 or H-6), 3.99 (1H, part A syst. AB, J = 11.3 Hz, H-11), 3.86 (1H, part B syst. AB, J = 11.3 Hz,
H-11’), 3.78 (3H, s, OCH3), 2.66 (1H, part A syst. AB, J = 17.7 Hz, H-4), 2.41 (1H, part B syst. AB, J = 17.7 Hz, H-4’),
1.58 (1H, br. s, OH), 1.20-0.76 (28H, m, TIPDS); 13C- NMR (75 MHz, CDCl3): δ 176.0, 159.4, 137.1, 132.7, 130.4, 129.1,
128.4, 128.3, 128.0, 126.3, 80.4, 76.3, 75.4, 70.3, 66.8, 64.3, 63.7, 55.2, 38.6, 17.5, 17.45, 17.4, 17.35, 17.3, 17.25,
13.3, 13.2, 12.9, 12.85; IR (film): v 3420, 3028, 2945, 2889, 2867, 1785, 1609, 1514, 1464, 1389, 1302, 1249, 1147,
1090, 1066, 1033, 1010, 922, 885, 800, 696 cm-1 ; LRMS (API- ES+): m/z 1389 (2M+Na)+, 706 (M+Na)+, 684 (M+H)+.
Claims
1. A process for rearranging the spirolactam of a compound of formula I
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wherein
R1 is selected from the group consisting of- H, -OH and -OPr1;
R2 is selected from the group consisting of -H, -CH2OH and -CH2OPr2; or
R1 and R2 together are =O, substituted or unsubstituted alkenyl, -CH2-O-, or- O- Prcy-O-CH2-;
R3 is selected from the group consisting of- H, -OH, -OPr3 and =O;
R4 is selected from the group consisting of -H, cyano, substituted or unsubstituted alkyl, -OPrl4, -OPr4, -OH,
substituted or unsubstituted alkenyl and substituted or unsubstituted alkynyl;
the dotted lines represent an optional additional bond;
if the double bond is present R5 is not present;
if the bond between C8 and C9 is a single bond, R5 is selected from the group consisting of-H, -OH and -OPr5; or
R4 and R5 together are =O; or
R3 and R5 or R3 and R2 together are -O-, forming an epoxide ring;
R6 is selected from -H, -OH, -OPrl6, -OPr6 and =O;
R7 is selected from the group consisting of -H, -OH, -OPr7 and =O; or
R7 and R6 together are -O-Prcy-O-;
Ra and Rb are each independently selected from the group consisting of -H, -OH, -OPrab, substituted or
unsubstituted alkyl, substituted or unsubstituted amino and halogen;
Pr1, Pr2, Pr3, Pr4, Pr5, Pr6, Pr7, Prey and Prab, are, the same or different, hydroxyl protecting groups;
Prl6 and Prl4 are acid labile hydroxyl protecting groups;
W is selected from the group consisting of -H, substituted or unsubstituted alkyl, substituted or unsubstituted
aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclyl and substituted or unsubsti-
tuted alkenyl;
or its tautomers, salts or solvates thereof;
wherein
A) if R4 is -OH or -OPrl4 and the compound of formula I is reacted with an acid reagent, a compound of formula
II is formed
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wherein R1, R2, R3, R6, R7, Ra, Rb and W are as defined in formula I; 
or its tautomers, salts or solvates thereof; or
B) if R6 is -OH or -OPrl6 and the compound of formula I is reacted with an acid reagent, a compound of formula
III is formed
wherein R1, R2, R3, R4, R5, R7, Ra, Rb and W are as defined in formula I; 
or its tautomers, salts or solvates thereof; or
C) if R4 is not -OH or -OPrl4, and R6 is not -OH or -OPrl6, and the compound of formula I is reacted with an acid
reagent or with halogen hydride, a compound of formula IV is formed
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wherein R1, R2, R3, R4, R5, R6, R7, Ra, Rb and W are as defined in formula I; or its tautomers, salts or solvates
thereof.
2. Process according to claim 1 which comprises reacting a compound of formula I as defined in claim 1, wherein R4
is selected from the group consisting of -OH and -OPrl4, and R1, R2, R3, R5, R6, R7, Ra, Rb and W are as defined
in claim 1 with an acid reagent to yield a compound of formula II as defined in claim 1.
3. Process according to claim 1 which comprises reacting a compound of formula I as defined in claim 1, wherein R6
is selected from the group consisting of -OH and -OPrl6, and R1, R2, R3, R4, R5, R7, Ra, Rb and W are as defined
in claim 1 with an acid reagent to yield a compound of formula III as defined in claim 1.
4. Process according to any of the previous claims, wherein Prl6 and Prl4 are independently selected from the group
consisting of silyl ethers of formula -Si (R’)3 or esters of formula -C (=O) R’; wherein R’ represents a substituent
selected from the group consisting of substituted of unsubstituted alkyl, substituted of unsubstituted alkenyl, sub-
stituted of unsubstituted alkynyl, substituted of unsubstituted aryl and substituted of unsubstituted aralkyl.
5. Process according to claim 4, wherein Prl6 and Prl4 are independently selected from the group consisting of trimeth-
ylsilyl ether, triethylsilyl ether, tert-butyldimethylsilyl ether, tert- butyldiphenylsilyl ether, tri-isopropylsilyl ether, diethyl-
isopropylsilyl ether, thexyldimethylsilyl ether, triphenylsilyl ether, di-tert- butylmethylsilyl ether, acetate ester, ben-
zoate ester, pivalate ester, chloroacetate ester and levulinate ester.
6. A Process according to any of the previous claims, wherein said acid reagent is selected form the group consisting
of silyl triflates, preferably TMSOTf, and diluted acids, preferably diluted sulphuric acid, diluted hydrochloric acid or
diluted acetic acid.
7. Process according to claim 1 which comprises reacting a compound of formula I as defined in claim 1, wherein R4
is not -OH or -OPrl4, R6 is not -OH or -OPrl6, and R1, R2, R3, R5, R7, Ra, Rb and W are as defined in claim 1 with
an acid reagent or with a halogen hydride, preferably sodium hydride, to yield a compound of formula IV as defined
in claim 1.
8. Process according to claim 7 which comprises reacting the compound of formula I, wherein one or more of R1, R2,
R3, R5, R7, Ra or Rb are OH, its tautomers, salts or solvates thereof, with a halogen hydride and an electrophile.
9. Process according to claim 8, wherein said electrophile has the general formula R8X, wherein X is a halogen atom,
and R8 is selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl,
substituted or unsubstituted aryl, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclyl, -C
(O) R9, -C(O) OR9 and -C(O) NR9R10, preferably substituted or unsubstituted aralkyl, wherein each of R9 and R10 is
independently selected from the group consisting of substituted or unsubstituted alkyl, substituted or unsubstituted
alkenyl, substituted or unsubstituted aryl, substituted or unsubstituted aralkyl and substituted or unsubstituted het-
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erocyclyl.
10. A compound of formula II as defined in claim 1 or its tautomers, salts or solvates thereof.
11. Compound according to claim 10, wherein R3 is -OH or -OPr3.
12. Compound according to any of claims 10 and 11, wherein R7 is -OH or -OPr7.
13. Compound according to any of claims 9 and 10, wherein at least one of Pr3 and Pr7 is also an acid labile hydroxyl
protecting group.
14. Compound according to claim 10, wherein R6 and R7 together are -O-Prcy-O-
15. Compound according to any of claims 10-14, wherein W in -CH2-Ph.
16. Compound according to claim 10 of formula IIb
wherein R1, R2, Ra, Rb and Prcy are as defined in claim 1; 
or its tautomers, salts or solvates thereof.
17. Compound according to claim 10, wherein the compound of formula II is selected from the group consisting of
rac-(1R,  5R,  6S,  7S,  8S,  9R)-  5-(benzyloxyamino)- 8-(benzoyloxymethyl)-  9-(tert-butyldimethylsilyloxy)- 6,7,8- trihy-
droxy-6,7-O-(1,1,3,3-tetraisopropyldisiloxano-1,3-diyl)-2-oxabicyclo[4.3.0] nonan- 3-one and rac- (1R, 5R, 6S, 7S, 8S,
9R)- 5-(benzyloxyamino)-8-(benzoyloxymethyl) -6,7,8,9-tetrahydroxy -6,7- O-(1,1,3,3- tetraisopropyldisiloxane- 1,3-
diyl)-2- oxabicyclo [4.3.0] nonan- 3-one, or its enantiomers, tautomers, salts or solvates thereof.
18. A compound of formula III as defined in claim 1 or its tautomers, salts or solvates thereof.
19. Compound according to claim 18, wherein R3 is -OH or -OPr3.
20. Compound according to any of claims 18 and 19, wherein R7 is -OH or -OPr7.
21. Compound according to any of claims 19 and 20, wherein at least one of Pr3 and Pr7 is also an acid labile hydroxyl
protecting group.
22. Compound according to any of claims 18-21, wherein W in -CH2-Ph.
23. Compound according to claim 18 of IIIb
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wherein R1, R2, Ra, Rb and Pr7 are as defined in claim 1;
or its tautomers, salts or solvates thereof
24. Compound according to 18, wherein the compound of formula III is selected from the group consisting of rac-(1S,
5R,9S)-5-(benzyloxyamino)- 9- hydroxy-2-oxabicyclo [4.3.0] non-6-en-3,8-dione, rac-(1S, 5R,9S)- 5-(benzyloxyami-
no)-9-(tert-butyldimethylsilyloxy)- 2- oxabicyclo[4.3.0]non-6- en-3,8-dione, rac-(1S, 5R,9S)- 5-(benzyloxyamino)-
9-(tert-butyldimethylsilyloxy)- 8- methylen-2-oxabicyclo [4.3.0] non-6-en-3-one, rac-(1S,5R, 9S)- 5-(benzyloxyamino)-
9-(tert-butyldimethylsilyloxy)- 8-hydroxy-8-hydroxymethyl-2-oxabicyclo[4.3.0] non-6-en- 3- one and rac-(1S,5R, 9S)-
5-(benzyloxyamino)-9-(tert- butyldimethylsilyloxy)- 8- hydroxy-8-(tert- butyldimethylsilyloxy methyl)- 2-oxabicyclo
[4.3.0] non-6-en- 3- one, or its enantiomers, tautomers, salts or solvates thereof.
25. A compound of formula IV as defined in claim 1 or its tautomers, salts or solvates thereof.
26. Compound according to claim 25 of formula IVb
wherein R1, R2, Ra, Rb, Prcy and W are as defined in claim 1;
or its tautomers, salts or solvates thereof
27. Compound according to claim 25, wherein the compound of formula IV is selected from the group consisting of
rac-(5R, 6S, 7S, 8R)- 1- benzyl- 6,7,8-trihydroxy-8-[(4-methoxybenzyloxy)methyl] -6,7- O-(1,1,3,3-tetraisopropyldisi-
loxane-1,3- diyl)- 1- aza- 2- oxaspiro[4.5] dec-9-en-3-one, rac-(5R,6S, 7S, 8R)-l- benzyl-6,7,8-trihydroxy-8-(hydroxyme-
thyl)-6,7- O-(1,1,3,3- tetraisopropyldisiloxane- 1,3-diyl)-1-aza- 2-oxaspiro[4.5] dec- 9-en-3-one, rac-(SR,6S, 7S)- 1-
benzyl-6,7- dihydroxy- 6,7- O-(1,1,3,3,-tetraisopropyl disiloxane-1,3-diyl)- 1- aza-2-oxaspiro[4.5] dec- 9-en-3,8- dione
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and rac-(5R, 6S, 7S)- 6,7-dihydroxy- 6,7-O-(1,1,3,3,-tetraisopropyldisiloxane- 1,3-diyl)-1-aza-2-oxaspiro [4.5] dec- 9-
en-3,8- dione, or its enantiomers, tautomers, salts or solvates thereof.
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